Longevity & Aging
resveratrol increases lifespan
In plain terms: Does resveratrol have real evidence it extends human lifespan or healthspan?
Contested Longevity & Aging 🔬 Includes disconfirming
Part of: 🧪 resveratrol
RefutedContestedStrong support
consensus score 0.02
Correct — no human longevity outcome exists and human metabolic RCTs are inconsistent/mostly null, so his dismissal of a longevity benefit holds (though "no effect whatsoever" would overreach).
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 2 contradict 6 tested null 4 mixed · 15 sources, 5 independent groups
What the evidence shows
Mouse benefit only on a high-fat diet (Baur-Sinclair 2006); NO extension on normal diet (Pearson 2008) and null in the NIA Interventions Testing Program (Miller 2011). No human outcome data.
The evidence (17)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Guevara-Cruz M, Sánchez-Tapia M, Velazquez-Villegas LA, Torre-Villalvazo I, Guizar-Heredia R, Godínez-Salas E, López-Barradas A, Granados O, Torres-Villalobos G, Torres N, Tovar AR 2025 · Eur J Nutr | RCT | mixed | moderate | HUMAN: 2-mo resveratrol improved insulin sensitivity, lean mass and lipids in obese/insulin-resistant subjects — a positive metabolic signal, but still no longevity/healthspan-lifespan endpoint. |
| Pollack RM, Barzilai N, Anghel V, Kulkarni AS, Golden A, O'Broin P, Sinclair DA, Bonkowski MS, Coleville AJ, Powell D, Kim S, Moaddel R, Stein D, Zhang K, Hawkins M, Crandall JP 2017 · J Gerontol A | RCT | supports | moderate | HUMAN: resveratrol improved vascular measures and mitochondrial number but NOT glucose metabolism in older adults; no longevity endpoint. |
| Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L 2007 · Mech Ageing Dev | animal | tested-null | high | No significant lifespan extension in Drosophila across 7 trials; C. elegans effects variable and SIR-2.1-independent - fails to replicate Sinclair invertebrate claim |
| Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D 2004 · Nature | animal | supports | moderate | Original STAC claim: resveratrol extended C. elegans/Drosophila lifespan, Sir2-dependent, no fecundity cost - landmark pro-claim, later poorly replicated ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
| Timmers S, de Ligt M, Phielix E, van de Weijer T, Hansen J, Moonen-Kornips E, Schaart G, Kunz I, Hesselink MK, Schrauwen-Hinderling VB, Schrauwen P 2016 · Diabetes Care | RCT | supports | moderate | HUMAN: resveratrol add-on in well-controlled T2D did NOT improve insulin sensitivity or metabolic health. |
| Chaplin A, Carpéné C, Mercader J 2018 · Nutrients | observational | mixed | low | Narrative review (JATS review-article) on metabolic syndrome and gut microbiota; lifespan appears only as background: 'resveratrol mimics calorie restriction effects through sirtuin 1 (SIRT1) activation, and thus extends the lifespan in simple organisms'. 'Clinical trials have been carried out to address its potential; however, results are still inconclusive.' Review — zero weight. |
| Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA 2006 · Nature | animal | mixed | moderate | Baur2006: survival gain ONLY in high-cal(obese) mice not standard diet; metabolic-rescue not true longevity |
| Sahebkar A 2013 · Nutr Rev | meta-analysis | tested-null | moderate | 7-RCT meta-analysis: resveratrol had no significant effect on any human plasma lipid - no cardiometabolic surrogate benefit underpinning longevity claim |
| Zhang J 2006 · Biochem J | in-vitro | mixed | moderate | Resveratrol inhibits insulin signaling SirT1-independently - mechanism may extend life via IIS pathway, but decouples effect from SIRT1 narrative |
| Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R 2011 · J Gerontol A | animal | contradicts | high | NIA ITP, genetically heterogeneous mice at three sites: 'Resveratrol (at 300 and 1200 ppm food) and simvastatin (12 and 120 ppm) did not have significant effects on survival in male or female mice', while rapamycin extended median survival 10% (males) and 18% (females). A null on this directional claim with a working positive control, so contradicts. Mouse data; abstract-grade. |
| Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS 2017 · J Neuroinflammation | observational | mixed | low | 52wk resveratrol in mild-moderate AD attenuated CSF Abeta40/ADL decline - modest disease-specific signal, not lifespan; possible immune modulation |
| Yadegar S, Mohammadi F, Yadegar A, Mohammadi Naeini A, Ayati A, Milan N, Tayebi A, Seyedi SA, Nabipoorashrafi SA, Rabizadeh S, Esteghamati A, Nakhjavani M 2024 · Phytother Res | observational | mixed | low | SR older adults: resveratrol no better than placebo in diabetes/PAD; high doses raised some CV-risk biomarkers - net unsupportive of longevity benefit |
| Huang H, Chen G, Liao D, Zhu Y, Pu R, Xue X 2016 · Obes Rev | meta-analysis | tested-null | moderate | Pooled RCTs overweight/obese: no significant effect of resveratrol on most CV-risk markers/body weight - human surrogate data do not support benefit |
| Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R 2008 · Cell Metab | animal | tested-null | high | Pearson2008: resveratrol does NOT increase longevity of ad-lib mice started midlife despite healthspan gains |
| Gliemann L, Schmidt JF, Olesen J, Biensø RS, Peronard SL, Grandjean SU, Mortensen SP, Nyberg M, Bangsbo J, Pilegaard H, Hellsten Y 2013 · J Physiol | RCT | contradicts | high | Resveratrol BLUNTED exercise-induced gains in VO2max, BP and lipids in aged men - actively harmful to a healthspan endpoint, opposite of claim |
| Rodrigues Uggioni ML, Ronsani L, Motta S, Denoni Júnior JC, Marçal F, Dagostin Ferraz S, Rosa MI, Colonetti T 2025 · Nutr Metab Cardiovasc Dis | meta-analysis | tested-null | moderate | SR/MA postmenopausal women: resveratrol did not significantly improve lipid profile - independent null on a longevity-relevant surrogate |
| de Ligt M, Bruls YMH, Hansen J, Habets MF, Havekes B, Nascimento EBM, Moonen-Kornips E, Schaart G, Schrauwen-Hinderling VB, van Marken Lichtenbelt W, Schrauwen P 2018 · Mol Metab | RCT | tested-null | moderate | HUMAN: improved ex-vivo mitochondrial function but NO effect on insulin sensitivity or BAT in T2D relatives. |
Considered, not graded (1)
Sources we looked at but did not score, and why. Radical transparency includes what we set aside.
- Combined resveratrol + nanodiamonds in Acheta domesticus (crickets) 2026 Below methodology floor
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.